A Review of Daclatasvir Drug-Drug Interactions.
The treatment of hepatitis C virus (HCV) infection has been revolutionized in recent years by the development of direct-acting antiviral regimens that do not contain peginterferon (pegIFN) and/or ribavirin (RBV). While direct-acting antiviral-based regimens have been shown to be greatly superior to pegIFN/RBV-based regimens in terms of efficacy and safety, they have a greater susceptibility to drug-drug interactions (DDIs). Daclatasvir (DCV)-the benchmark pangenotypic nonstructural protein 5A inhibitor-has been shown to be efficacious and generally well tolerated in partnership with other HCV direct-acting antivirals, including sofosbuvir, asunaprevir (ASV), and ASV plus beclabuvir. DCV may be the object of a DDI via the induction or inhibition of cytochrome P450 (CYP) 3A4 and/or P-glycoprotein (P-gp) by the concomitant medication, or the precipitant of a DDI via DCV-based induction/inhibition of CYP 3A4 or inhibition of P-gp, organic anion transporting polypeptide 1B1/B3, and/or breast cancer resistance protein. This article presents an overview of the drug interaction studies conducted during the clinical development of DCV, the findings of these studies that led to the guidance on concomitant medication use and dosage along with any required DCV dose modifications, and the use of the known metabolic pathway of DCV to guide concomitant dosing where direct drug-drug studies have not been conducted. The robust characterization of the DCV clinical pharmacology program has demonstrated that DCV has few or no clinically relevant DDIs with medications with which it is likely to be co-administered, and the majority of DDIs that do occur can be predicted and easily managed.



Bristol-Myers Squibb.
Bristol-Myers Squibb Research and Development, Lawrenceville, NJ, USA. tushar.garimella@bms.com.
Tushar
T
Garimella
Bristol-Myers Squibb Research and Development, Lawrenceville, NJ, USA.
Xiaoli
X
You
Bristol-Myers Squibb Research and Development, Lawrenceville, NJ, USA.
Reena
R
Wang
Bristol-Myers Squibb Research and Development, Lawrenceville, NJ, USA.
Shu-Pang
SP
Huang
Bristol-Myers Squibb Research and Development, Lawrenceville, NJ, USA.
Hamza
H
Kandoussi
Bristol-Myers Squibb Research and Development, Lawrenceville, NJ, USA.
Marc
M
Bifano
Bristol-Myers Squibb Research and Development, Hopewell, NJ, USA.
Richard
R
Bertz
Bristol-Myers Squibb Research and Development, Lawrenceville, NJ, USA.
Timothy
T
Eley
D000998:Antiviral Agents / Q000494:pharmacology; D002219:Carbamates; D004347:Drug Interactions; D004359:Drug Therapy, Combination / Q000379:methods; D016174:Hepacivirus / Q000187:drug effects; D019698:Hepatitis C, Chronic / Q000188:drug therapy*; D006801:Humans; D007093:Imidazoles / Q000494:pharmacology*; D011759:Pyrrolidines; D014633:Valine / Q000031:analogs & derivatives
D000998:Antiviral Agents; D002219:Carbamates; D007093:Imidazoles; D011759:Pyrrolidines; D014633:Valine; C549273:daclatasvir
Concomitant medications; Daclatasvir; Drug–drug interactions; Hepatitis C virus; Infectious diseases
N Engl J Med. 2015 Aug 20;373(8):714-25
26196502
Lancet. 2011 Aug 13;378(9791):571-83
21802134
Clin Drug Investig. 2015 May;35(5):281-9
25896946
Hepatology. 2020 Feb;71(2):686-721
31816111
Antivir Ther. 2014;19(5):511-9
24343001
Adv Ther. 2015 Jul;32(7):637-49
26155891
Antivir Ther. 2013;18(7):931-40
23963204
JAMA. 2015 May 5;313(17):1728-35
25942723
Clin Drug Investig. 2014 Sep;34(9):661-71
25117173
Biochim Biophys Acta. 2002 Dec 16;1593(1):93-8
12431788
Antimicrob Agents Chemother. 2015 Dec;59(12):7903-5
26438504
Clin Pharmacol Ther. 2001 Jan;69(1):14-23
11180034
Prim Care Companion J Clin Psychiatry. 2005;7(5):225-30
16308578
Clin Pharmacokinet. 2015 Dec;54(12):1205-22
26177803
Curr Infect Dis Rep. 2012 Feb;14(1):67-82
22125049
Hepatology. 2016 May;63(5):1493-505
26754432
Lancet Infect Dis. 2016 Jul;16(7):797-808
26922272
Clin Infect Dis. 2016 Mar 1;62(5):561-7
26611779
JAMA. 2015 May 5;313(17):1736-44
25942724
Nat Rev Gastroenterol Hepatol. 2013 Oct;10(10):596-606
23817323
Planta Med. 2012 Sep;78(13):1490-514
22565299
Hepatology. 2016 May;63(5):1430-41
26822022
Hepatology. 2014 Jun;59(6):2083-91
24604476
Antimicrob Agents Chemother. 2015 Sep;59(9):5503-10
26124175
J Clin Gastroenterol. 2006 Mar;40(3):220-4
16633123